New Age Alpha Advisors LLC Makes New $4.57 Million Investment in IQVIA Holdings Inc. (NYSE:IQV)

New Age Alpha Advisors LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 23,228 shares of the medical research company’s stock, valued at approximately $4,565,000.

Other hedge funds have also modified their holdings of the company. Intech Investment Management LLC bought a new stake in IQVIA in the third quarter valued at approximately $223,000. Algert Global LLC bought a new stake in shares of IQVIA in the 3rd quarter valued at $514,000. Larson Financial Group LLC raised its stake in IQVIA by 745.1% during the 3rd quarter. Larson Financial Group LLC now owns 431 shares of the medical research company’s stock worth $102,000 after buying an additional 380 shares during the period. Fisher Asset Management LLC lifted its holdings in IQVIA by 4.8% during the third quarter. Fisher Asset Management LLC now owns 7,398 shares of the medical research company’s stock worth $1,753,000 after acquiring an additional 341 shares in the last quarter. Finally, Private Trust Co. NA grew its stake in IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 47 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 1.2 %

NYSE IQV opened at $177.27 on Friday. The company has a market cap of $31.25 billion, a PE ratio of 23.64, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 12 month low of $176.03 and a 12 month high of $253.84. The stock has a 50 day moving average of $193.15 and a 200-day moving average of $206.47. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on IQV. Barclays cut their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Truist Financial reaffirmed a “buy” rating and issued a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Citigroup cut their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. lowered their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.